48例腮腺黏液表皮样癌病理和临床分析  

Clinical and pathological analysis of mucoepidermoid carcinoma of parotid 48 cases

作　　者：郝汉霞[1] 刘力嘉[2] 夏雷[3] 张园[1] 

机构地区：[1]江苏省肿瘤医院头颈外科,江苏南京210009 [2]南京医科大学第一附属医院普外科,江苏南京210029 [3]江苏省肿瘤医院病理科,江苏南京210009

出　　处：《口腔生物医学》2011年第4期192-195,共4页Oral Biomedicine

摘　　要：目的:探讨腮腺黏液表皮样癌(mucoepidermoid cancer,MEC)的病理诊断、治疗和预后。方法:分析48例腮腺黏液表皮样癌的临床和病理特征,进行P53免疫组化检查,观察其与临床、病理分级、预后的关系。结果:48例病例中,男25例,女23例,平均43岁,多数首发症状为无痛性肿块,部分伴疼痛、面瘫及淋巴结转移,病程2周至8年不等,平均1年3个月。所有病例均行P53免疫组化染色,病理分级为高、中、低分化三组,其阳性率分别为54.5%、80%和100%。随访高、中、低分化组5年生存率分别为97%、90%、60%;临床Ⅰ、Ⅱ期和临床Ⅲ、Ⅳ期5年生存率分别为100%、55.6%。结论:腮腺黏液表皮样癌手术方案应综合考虑临床分期和病理分化程度。P53对判断腮腺MEC的分化程度、评估预后有一定的意义。Objective： To explore the diagnosis, treatment and prognosis of parotid mucoepidermoid cancer （MEC）. Methods： Clinical and pathological features were analyzed on 48 cases of MEC and were stained on P53 by immunohistochemistry. Results： In 48 follow-up cases, P53 immunopositive rate was 54.5% in low degree malignancy, 80% in moderate degree malignancy, 100% in high degree malignancy. 33 cases of low degree malignancy with 5 years survival rate was 97% , 10 cases of moderate degree malignancy with 5 years survival rate 90% , 5 cases of high degree malignancy with 5 years survival rate 60%. 39 cases of clinical Ⅰ , Ⅱ with 5 years survival rate was 100%, 9 cases of clinica Ⅲ, Ⅳ with 5 years survival rate 55.6%. Conclusions：P53 can be used for the evaluation of the degree malignancy and prognosis of parotid mucoepidermoid cancer. There＇s great difference in treatment measure and prognosis between high degree mucoepidermoid cancer and low degree mucoepidermoid cancer. The correct diagnosis and standardized treatment is the key to improvement of prognosis.

关 键 词：腮腺 黏液表皮样癌 免疫组织化学 P53 手术 放疗 化疗 

分 类 号：R739.87[医药卫生—肿瘤]